Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 26, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 60,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,470.6214 pence per share.
- Treasury Holdings: 290,182,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,728,715,957 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 60,000 shares on April 26, 2007. These shares are intended to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (290,182,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total voting rights denominator (5,728,715,957) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.